No. of vaccines administered at Semmelweis University - 29 January 2023
545342 Total vaccines

Present appointment: Scientific Advisor

Phone: +36 1 210 29 30/Ext. 56393

Email: harsing,

Education and qualification:

  • 1966-1972, Semmelweis University, Faculty of Medicine, Budapest

Present affiliation:

  • 2009- Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest

Previous affiliations, Hungary:

  • 1973-1981 Assistant Professor, Department of Pharmacology, Semmelweis University
  • 1981-1986 Senior Research Fellow, Institute of Experimental Medicine, Hungarian Academy of Sciences
  • 1986-1995 Associate Professor Department of Pharmacology, Postgraduate School of Medicine, Budapest
  • 1992-2000 Vice Director, Institute for Drug Research, Budapest
  • 2000-2008 Vice Director, EGIS Pharmaceuticals Plc, Budapest

Previous affiliations, USA:

  • 1980-1981 National Institute of Mental Health, Washington, DC
  • 1985-1986 Montefiore Hospital, Albert Einstein Colloge of Medicine, New York, NY
  • 1989-1992 Center for Neurochemistry, New York University, Orangeburg, NY
  • 1995-1996 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA

Educational activities:

  • Lecturing in pharmacology at universities and in postgraduate and PhD schools, graduate and postgraduate levels in Hungarian and English

Scientific Qualifications:

  • 1984, PhD, Regulation of Cholinergic Neurotransmission in the Striatum
  • 1992, DSc, Heterogeneity of Alpha-2 Adrenoceptors
  • 1994, Lecturer in Pharmacology (Dr. Med. Habil.)

Merits and Awards:

  • Fogarty International Fellowship, National Institutes of Health, 1980,1995
  • Issekutz Memorial Medal, Hungarian Pharmacological Society, 2000
  • Order of Merit of Hungary 2018

Research areas:

  • experimental pharmacology, academic and industrial
  • neuropsychopharmacology, neurotransmitter release, neurochemistry

Scientific publications and Scientometric data:

  • scientific publications: 272
    Chapters in textbooks: 39
    Abstracts in journals and proceedings: 60
    Patents in pharmaceutical drug development: 42
    Cumulative impact factor: 259,869
    Number of citations: independent 2436, total 3237
    Hirsh index: 33

Drug development in preclinical phases:

  • azidoethylmorphine, antitussive drug
  • SCT-66, α2 adrenoceptor antagonist, antidepressant drug, US 4,851,416
  • GYKI-46903, non-competitive 5-HT3 receptor antagonist
  • EGIS-14111, glycine transporter-1 inhibitor
  • (-)BPAP, catecholaminergic activity enhancer drug

Drug development in clinical phase:

  • EGIS-11150/S36549, atypical antipsychotic, schizophrenia, US 20050043314 A1, Phase I clinical trial
  • GYKI-16084, postsynaptic α1 and α2 adrenoceptor antagonist, benign prostate hyperplasia, US 619441 B1, Phase II clinical trial
  • EGIS-13529/S44819, α5 GABAA receptor inverse agonist, post-stroke recovery, US 20120232065 A1, Completed phase II clinical trial

Editorial activities in periodicals:

  • Neurochemical Research, Associate Editor
  • Neurochemistry International, Current Medicinal Chemistry, memberships in editorial boards

Membership in professional societies:

  • Hungarian Pharmacological Society
  • Hungarian Physiological Society
  • Society for Neuroscience, USA
  • European Society for Neuroscience
  • Australian Neuroscience Society
  • Society of Neuroscience in Africa (SONA)
  • International Society for Neurochemistry